RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3B FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3B FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3B FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to rescue patients from Hard-to-Treat lymphoma
Disease control TerminatedThis phase II trial tests a two-step approach for people with relapsed or refractory large B-cell lymphoma who are eligible for a stem cell transplant. First, patients receive tafasitamab (an antibody) plus lenalidomide, followed by tafasitamab combined with ICE chemotherapy. The…
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to outsmart Hard-to-Treat lymphoma
Disease control OngoingThis phase 2 trial tests a combination of two drugs—TTI-622 and pembrolizumab (Keytruda)—in about 10 adults with diffuse large B-cell lymphoma that has come back or not responded to treatment. TTI-622 blocks a protein called CD47 that cancer cells use to hide from the immune syst…
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Experimental drug boosts Cancer-Killing cells in lymphoma trial
Disease control OngoingThis early-phase trial tests whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to treatment. The study involves 27 adults and focuses on safety and how w…
Matched conditions: RECURRENT GRADE 3B FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC